申请人:——
公开号:US06087359A1
公开(公告)日:2000-07-11
A thioaryl sulfonamide hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated thioaryl sulfonamide hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
本文披露了一种硫芳基磺酰胺羟肟酸化合物,该化合物在抑制基质金属蛋白酶活性方面起作用,还披露了一种治疗过程,包括向患有与病理性基质金属蛋白酶活性相关的病症的宿主施用所考虑的硫芳基磺酰胺羟肟酸化合物,施用剂量为MMP酶抑制有效量。